Discovery of Novel Myc−Max Heterodimer Disruptors with a Three-Dimensional Pharmacophore Model
- 12 February 2009
- journal article
- letter
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (5) , 1247-1250
Abstract
A three-dimensional pharmacophore model was generated utilizing a set of known inhibitors of c-Myc−Max heterodimer formation. The model successfully identified a set of structurally diverse compounds with potential inhibitory activity against c-Myc. Nine compounds were tested in vitro, and four displayed affinities in the micromolar range and growth inhibitory activity against c-Myc-overexpressing cells. These studies demonstrate the applicability of pharmacophore modeling to the identification of novel and potentially more puissant inhibitors of the c-Myc oncoprotein.Keywords
This publication has 27 references indexed in Scilit:
- Intrinsically Disordered Proteins in Human Diseases: Introducing the D2ConceptAnnual Review of Biophysics, 2008
- Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in miceCancer Chemotherapy and Pharmacology, 2008
- Reaching for high-hanging fruit in drug discovery at protein–protein interfacesNature, 2007
- Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening dataMolecular Cancer Therapeutics, 2007
- Selective Inhibition of c-Myc/Max Dimerization and DNA Binding by Small MoleculesChemistry & Biology, 2006
- Evaluation of “Credit Card” Libraries for Inhibition of HIV-1 gp41 Fusogenic Core FormationJournal of Combinatorial Chemistry, 2006
- Evaluating Chemical Structure Similarity as an Indicator of Cellular Growth InhibitionJournal of Chemical Information and Modeling, 2005
- C-Myc–Independent Restoration of Multiple Phenotypes by Two C-Myc Target Genes with Overlapping FunctionsCancer Research, 2005
- Do Structurally Similar Molecules Have Similar Biological Activity?Journal of Medicinal Chemistry, 2002
- Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosynthesesEuropean Journal of Medicinal Chemistry, 1994